Tag : biopharmaceutical company

Healthcare Quality, Patient Safety & Policy

Innovent & HUTCHMED NDA Accepted for Sintilimab Combo in China

PR Newswire
by PR Newswire0116
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
Clinical Research, Pharma & Healthcare Financing

InnoCare Gets OK to Trial Mesutoclax for MDS in China

Business Wire
by Business Wire0119
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND)...
Clinical Research, Pharma & Healthcare Financing

Rznomics Partners with Eli Lilly for RNA-editing Therapeutics Licensing

PR Newswire
by PR Newswire0162
Co-development of precision RNA therapeutics for inherited hearing loss treatment Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has...
Clinical Research, Pharma & Healthcare Financing

Alchemab signs $415M licensing deal for ATLX-1282 with Eli Lilly

PR Newswire
by PR Newswire0178
New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism Deal worth up to $415m including upfront...
Clinical Research, Pharma & Healthcare Financing

Innovent Doses First Patient in Phase 1 Trial of IBI3020 ADC

PR Newswire
by PR Newswire0157
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology...
Clinical Research, Pharma & Healthcare Financing

AbolerIS Pharma Announces Formation of Scientific Advisory Board

PR Newswire
by PR Newswire0134
AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation of...
Workforce Development & Leadership

Scholar Rock Grants Employee Inducement Awards Under Nasdaq Rule

Business Wire
by Business Wire0137
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today...
Clinical Research, Pharma & Healthcare Financing

Precigen & RRP Foundation to Host 2025 RRP Awareness Day

PR Newswire
by PR Newswire0221
– International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic...
Healthcare Quality, Patient Safety & Policy

Boehringer Ingelheim, Cue Biopharma Partner on Autoimmune Therapies

GlobeNewswire
by GlobeNewswire0189
Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a...
Clinical Research, Pharma & Healthcare Financing

Oculis Hosts R&D Event to Share Pipeline Progress Today

GlobeNewswire
by GlobeNewswire0181
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with...